BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

192 related articles for article (PubMed ID: 32107398)

  • 1. Identifying relationships between imaging phenotypes and lung cancer-related mutation status: EGFR and KRAS.
    Pinheiro G; Pereira T; Dias C; Freitas C; Hespanhol V; Costa JL; Cunha A; Oliveira HP
    Sci Rep; 2020 Feb; 10(1):3625. PubMed ID: 32107398
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Next-Generation Radiogenomics Sequencing for Prediction of EGFR and KRAS Mutation Status in NSCLC Patients Using Multimodal Imaging and Machine Learning Algorithms.
    Shiri I; Maleki H; Hajianfar G; Abdollahi H; Ashrafinia S; Hatt M; Zaidi H; Oveisi M; Rahmim A
    Mol Imaging Biol; 2020 Aug; 22(4):1132-1148. PubMed ID: 32185618
    [TBL] [Abstract][Full Text] [Related]  

  • 3. CT-based non-invasive identification of the most common gene mutation status in patients with non-small cell lung cancer.
    Chen Z; Gao S; Ding C; Luo T; Xu J; Xu S; Li S
    Med Phys; 2024 Mar; 51(3):1872-1882. PubMed ID: 37706584
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Machine Learning-Based Radiomics Signatures for EGFR and KRAS Mutations Prediction in Non-Small-Cell Lung Cancer.
    Le NQK; Kha QH; Nguyen VH; Chen YC; Cheng SJ; Chen CY
    Int J Mol Sci; 2021 Aug; 22(17):. PubMed ID: 34502160
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Impact of feature harmonization on radiogenomics analysis: Prediction of EGFR and KRAS mutations from non-small cell lung cancer PET/CT images.
    Shiri I; Amini M; Nazari M; Hajianfar G; Haddadi Avval A; Abdollahi H; Oveisi M; Arabi H; Rahmim A; Zaidi H
    Comput Biol Med; 2022 Mar; 142():105230. PubMed ID: 35051856
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Role of [¹⁸F]FDG PET in prediction of KRAS and EGFR mutation status in patients with advanced non-small-cell lung cancer.
    Caicedo C; Garcia-Velloso MJ; Lozano MD; Labiano T; Vigil Diaz C; Lopez-Picazo JM; Gurpide A; Zulueta JJ; Richter Echevarria JA; Perez Gracia JL
    Eur J Nucl Med Mol Imaging; 2014 Nov; 41(11):2058-65. PubMed ID: 24990403
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Correlation of EGFR or KRAS mutation status with 18F-FDG uptake on PET-CT scan in lung adenocarcinoma.
    Takamochi K; Mogushi K; Kawaji H; Imashimizu K; Fukui M; Oh S; Itoh M; Hayashizaki Y; Ko W; Akeboshi M; Suzuki K
    PLoS One; 2017; 12(4):e0175622. PubMed ID: 28422979
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Response rate of patients with baseline brain metastases from recently diagnosed non-small cell lung cancer receiving radiotherapy according to EGFR, ALK and KRAS mutation status.
    Arrieta O; Ramírez-Tirado LA; Caballé-Perez E; Mejia-Perez A; Zatarain-Barrón ZL; Cardona AF; Lozano-Ruíz F; Segura-González M; Cruz-Rico G; Maldonado F; Rosell R
    Thorac Cancer; 2020 Apr; 11(4):1026-1037. PubMed ID: 32072746
    [TBL] [Abstract][Full Text] [Related]  

  • 9. FDG uptake in non-small cell lung cancer is not an independent predictor of EGFR or KRAS mutation status: a retrospective analysis of 206 patients.
    Lee SM; Bae SK; Jung SJ; Kim CK
    Clin Nucl Med; 2015 Dec; 40(12):950-8. PubMed ID: 26359571
    [TBL] [Abstract][Full Text] [Related]  

  • 10. EGFR and KRAS molecular genotyping for pulmonary carcinomas: Feasibility of a simple and rapid technique implementable in any department of pathology.
    Thomas De Montpréville V; Ghigna MR; Lacroix L; Lemoine A; Besse B; Mercier O; Fadel É; Dorfmuller P; Le Chevalier T;
    Pathol Res Pract; 2017 Jul; 213(7):793-798. PubMed ID: 28554746
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Dual-energy spectral CT characteristics in surgically resected lung adenocarcinoma: comparison between Kirsten rat sarcoma viral oncogene mutations and epidermal growth factor receptor mutations.
    Li M; Zhang L; Tang W; Duan JC; Jin YJ; Qi LL; Wu N
    Cancer Imaging; 2019 Nov; 19(1):77. PubMed ID: 31783917
    [TBL] [Abstract][Full Text] [Related]  

  • 12. CT Radiogenomic Characterization of EGFR, K-RAS, and ALK Mutations in Non-Small Cell Lung Cancer.
    Rizzo S; Petrella F; Buscarino V; De Maria F; Raimondi S; Barberis M; Fumagalli C; Spitaleri G; Rampinelli C; De Marinis F; Spaggiari L; Bellomi M
    Eur Radiol; 2016 Jan; 26(1):32-42. PubMed ID: 25956936
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A Radiogenomics Ensemble to Predict EGFR and KRAS Mutations in NSCLC.
    Moreno S; Bonfante M; Zurek E; Cherezov D; Goldgof D; Hall L; Schabath M
    Tomography; 2021 Apr; 7(2):154-168. PubMed ID: 33946756
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Genomics of non-small cell lung cancer (NSCLC): Association between CT-based imaging features and EGFR and K-RAS mutations in 122 patients-An external validation.
    Rizzo S; Raimondi S; de Jong EEC; van Elmpt W; De Piano F; Petrella F; Bagnardi V; Jochems A; Bellomi M; Dingemans AM; Lambin P
    Eur J Radiol; 2019 Jan; 110():148-155. PubMed ID: 30599853
    [TBL] [Abstract][Full Text] [Related]  

  • 15. PD-1/PD-L1 expression in non-small-cell lung cancer and its correlation with EGFR/KRAS mutations.
    Ji M; Liu Y; Li Q; Li X; Ning Z; Zhao W; Shi H; Jiang J; Wu C
    Cancer Biol Ther; 2016 Apr; 17(4):407-13. PubMed ID: 26954523
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Detection of Loss of Heterozygosity in cfDNA of Advanced
    Boldrin E; Nardo G; Zulato E; Bonanno L; Polo V; Frega S; Pavan A; Indraccolo S; Saggioro D
    Int J Mol Sci; 2019 Dec; 21(1):. PubMed ID: 31861832
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Association of EGFR and KRAS mutations with expression of p-AKT, DR5 and DcR1 in non-small cell lung cancer.
    Zhao XD; Deng HB; Lu CL; Bao YX; Lu X; Deng LL
    Neoplasma; 2017; 64(2):182-191. PubMed ID: 28043144
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Associations Between Somatic Mutations and Metabolic Imaging Phenotypes in Non-Small Cell Lung Cancer.
    Yip SS; Kim J; Coroller TP; Parmar C; Velazquez ER; Huynh E; Mak RH; Aerts HJ
    J Nucl Med; 2017 Apr; 58(4):569-576. PubMed ID: 27688480
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Imaging Characteristics of Driver Mutations in EGFR, KRAS, and ALK among Treatment-Naïve Patients with Advanced Lung Adenocarcinoma.
    Park J; Kobayashi Y; Urayama KY; Yamaura H; Yatabe Y; Hida T
    PLoS One; 2016; 11(8):e0161081. PubMed ID: 27518729
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Screening for EGFR and KRAS mutations in non-small cell lung carcinomas using DNA extraction by hydrothermal pressure coupled with PCR-based direct sequencing.
    Liu Y; Wu BQ; Zhong HH; Hui P; Fang WG
    Int J Clin Exp Pathol; 2013; 6(9):1880-9. PubMed ID: 24040454
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.